Paclitaxel, carboplatin, and extended sc
β
John D. Hainsworth; Steven L. Stroup; F. Anthony Greco
π
Article
π
1996
π
John Wiley and Sons
π
English
β 577 KB
## BACKGROUND. Paclitaxel is an active agent in the initial treatment of patients with small cell lung carcinoma. The authors evaluated the toxicity and efficacy of paclitaxel (1-hour infusion) added to a standard combination regimen of carboplatin and etoposide in a Phase I1 trial for the treatme